Hui Wang
Impact in
- Cancer Research top 0.5%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Cancer, Hypoxia, and Metabolism
- Pathology and Forensic Medicine top 0.5%
- Vitamin D Research Studies
Papers in
-
- RNA modifications and cancer 23
- Circular RNAs in diseases 13
-
- Cancer-related molecular mechanisms research 29
- MicroRNA in disease regulation 12
- Co-authors
- Jingquan Li (34 shared papers)Peizhan Chen (22 shared papers)Qian Ba (31 shared papers)Dong Xie (6 shared papers)Ruiai Chu (14 shared papers)Haiyun Song (17 shared papers)Xiaoguang Li (16 shared papers)Wenbo Yao (6 shared papers)
- Journals
- PLoS ONE (8 papers)Medicine (5 papers)Frontiers in Immunology (4 papers)EBioMedicine (4 papers)Frontiers in Pharmacology (4 papers)
- Partner nations
- ChinaUnited StatesUnited Kingdom
In The Last Decade
Hui Wang
258 papers receiving 8.9k citations
Hui Wang's Hit Papers
Peers
Comparison fields: 5 of 171
- Cancer Research 1.9k
- Pathology and Forensic Medicine 1.1k
- Molecular Biology 3.6k
- Immunology 1.0k
- Oncology 1.2k
Countries citing papers authored by Hui Wang
This map shows the geographic impact of Hui Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hui Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hui Wang more than expected).
Fields of papers citing papers by Hui Wang
This network shows the impact of papers produced by Hui Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hui Wang. The network helps show where Hui Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Hui Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 269 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma Hit paper breakdown → | 2015 | 605 |
| 2 | STAT3-mediated upregulation of lncRNA HOXD-AS1 as a ceRNA facilitates liver cancer metastasis by regulating SOX4 Hit paper breakdown → | 2017 | 437 |
| 3 | 2018 | 346 | |
| 4 | 2009 | 233 | |
| 5 | 2008 | 161 | |
| 6 | 2016 | 154 | |
| 7 | 2018 | 152 | |
| 8 | 2017 | 141 | |
| 9 | 2017 | 139 | |
| 10 | 2015 | 134 | |
| 11 | 2014 | 124 | |
| 12 | 2020 | 121 | |
| 13 | 2020 | 118 | |
| 14 | 2015 | 109 | |
| 15 | 2010 | 107 | |
| 16 | 2020 | 105 | |
| 17 | 2009 | 103 | |
| 18 | 2019 | 101 | |
| 19 | 2014 | 101 | |
| 20 | 2014 | 100 |
About Hui Wang
Hui Wang is a scholar working on Molecular Biology, Cancer Research, Pathology and Forensic Medicine, Surgery and Oncology, having authored 269 papers that have together received 9.0k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (29 papers), RNA modifications and cancer (23 papers), Circular RNAs in diseases (13 papers), MicroRNA in disease regulation (12 papers), Vitamin D Research Studies (11 papers), Parasitic infections in humans and animals (9 papers), Tea Polyphenols and Effects (9 papers) and Cancer Immunotherapy and Biomarkers (8 papers). The work is most often cited by research in Cancer Research (1.9k citations), Pathology and Forensic Medicine (1.1k citations), Molecular Biology (3.6k citations), Immunology (1.0k citations) and Oncology (1.2k citations). Hui Wang has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Jingquan Li, Peizhan Chen, Qian Ba, Dong Xie, Ruiai Chu, Haiyun Song, Xiaoguang Li, Wenbo Yao, Mian Li and Ruiwen Zhang. Their work appears in journals such as PLoS ONE, Medicine, Frontiers in Immunology, EBioMedicine and Frontiers in Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.